



# **Capital Market Update**


**May 2021**

Karan Vora


Economic Update
<ul style="list-style-type: none"><li>• Manufacturing IIP Data - MOSPI</li></ul>
Secondary Market Update
Primary Market Update
<ul style="list-style-type: none"><li>• Initial Public Offers (IPOs)</li></ul>
Mergers & Acquisitions Key Deals
<ul style="list-style-type: none"><li>• BYJU'S to acquire Aakash Institute</li><li>• Piramal Pharma Ltd. to Acquire Hemmo Pharmaceuticals</li></ul>
Private Equity Key Deals
<ul style="list-style-type: none"><li>• Chrys Capital invests in Corona Remedies, Creador exits</li></ul>

- Department of Economic affair has stated that that the rapid resurgence in Covid-19 cases, especially in India, has moderated the momentum of economic recovery.
- The IIP (Index of Industrial Production) data showed that manufacturing Index was at its highest in last 15 months in March 2021. However, it is to be noted that the IIP data does not capture the impact of second Covid-19 wave which poses downside risk to economic activity.
- At the same time, agriculture and rural demand will continue to be the silver lining due to forecast of normal monsoon.
- In its first monetary policy statement for 2021-22, the Reserve Bank retained its projection of real GDP growth for the year at 10.5 per cent.
- Collections under the goods and services tax (GST) in April 2021 recorded a new high of Rs. 1.41 lakh Crore, remaining above the Rs. 1 lakh crore mark for the sixth consecutive month despite of Covid 2nd wave.

Manufacturing IIP Data - MOSPI




- BSE Sensex went down by 1.47% in April 2021 to close at 48,782. Nifty 50 closed at 14,631 lower by 0.41% from 14,691 in March closing.
- Investor sentiments were weak in April on account of 2<sup>nd</sup> Covid wave with record infections, stricter lockdowns and low demand. However company report cards of Q4FY21 were largely positive which supported the markets.
- Foreign Portfolio Investors (FPI) divested Rs. 9,659 Crore from the Indian equity markets in the month of April.



Equity Markets	Mar-21	Apr-21	Change%
<b>Sensex</b>	49,509	48,782	-1.47%
<b>Nifty 50</b>	14,691	14,631	-0.41%
<b>BSE 500</b>	19,602	19,690	0.45%
<b>BSE Bankex</b>	37,547	37,305	-0.64%
<b>BSE Consumer Durables</b>	32,826	32,325	-1.53%
<b>BSE Healthcare</b>	21,328	23,531	10.33%
<b>BSE FMCG</b>	12,875	12,509	-2.85%

# Performance of BSE sectoral Indices in % in April 2021

- Amongst the BSE sectoral indices Metal (24.19%) and Healthcare (10.33%) were the best performers while Realty and Capital Goods sectors were the laggards.
- Metal sector has saw action due to pick up in global demands and increase in metal prices of Steel, copper and aluminum. Indian Steel demand is likely to be strong in FY22.



- There were two main board IPOs of Macrotech Developers Limited and Barbeque Nation Hospitality Limited in April 2021 as against nine main board IPOs March 2021. Both IPOs were listed at discount on opening day due to relatively weak investor sentiments.
- There were three SME IPOs of Jetmall Spices and Masala Limited, Rajeshwari Cans Limited and EKI Energy Services Limited in April 2021 as against two SME IPOs of Rangoli Tradecomm Limited and Knowledge Marine & Engineering Works Limited in March 2021.

## Funds Mobilisation by Corporates (₹ in Crore)

Particulars	Jan-21	Feb-21
<b>I. Equity Issue</b>	<b>11,517</b>	<b>14,517</b>
a. IPOs (i+ii)	4,933	3,658
i. Main Board	4,933	3,655
ii. SME Platform	-	3
b. FPOs	-	-
c. Equity Rights Issue	81	2,999
d. QIP/IPP	1,170	2,645
e. Preferential Allotment	5,333	5,216
<b>II. Debt Issue</b>	<b>61,224</b>	<b>45,902</b>
a. Debt Public Issue	5,600	216
b. Private Placement of Debt	55,624	45,685
<b>Total Funds Mobilised (I+II)</b>	<b>72,741</b>	<b>60,419</b>

- Established in 1995, Macrotech Developers is a real estate developer in India. The company is primarily engaged in affordable residential real estate developments.
- It has also entered into the development of logistics and industrial parks and also develops commercial real estate. The price band of IPO was Rs.483-486 per share and it was subscribed 1.36 times. Amount raised through IPO was about Rs.2500 crore.
- IPO got listed at Rs.439 at 9.67 per cent discount to its issue price of Rs.486 per share.
- IPO proceeds will be used for reducing debt by up to Rs.1500 crore and also to acquire land or land developmental rights aggregating up to Rs.375 crore.



- Incorporated in 2006, Barbeque Nation Restaurants is a casual dining restaurant chain in India. The first Barbeque Nation Restaurant was established in 2008 and it has grown to 138 Barbeque Nation Restaurants in 73 cities in India and 7 International Barbeque Nation Restaurants in 3 countries outside India.
- The price band of the IPO was Rs.498-500 per share.
- Amount raised by the IPO was Rs.453 crore.
- The share was listed at Rs.492 on BSE at a 1.6 per cent discount over its issue price of Rs.500. At the issue price, the company had a valuation of 2.4x FY20 EV/sales.

# Mergers & Acquisitions Key Deals

## Transaction:

- BYJU'S has announced to acquire Aakash Educational Services Limited (AESL) through a strategic merger in a nearly \$1 Billion deal.
- Aakash founders JC Chaudhry and Aakash Chaudhry will continue to lead AESL's growth and expansion. Aakash founders along with investor Blackstone will become shareholders in BYJU'S.

## BYJU'S:

- BYJU'S is an education-tech company which offers learning programs for students from classes 1 -12 (K-12) to competitive exams.
- Today, the app has over 80 million registered students and 5.5 million annual paid subscriptions (In our October 2020 write up, this number was 50 million registered users and over 3.5 million paid subscriptions). It was widely reported that the platform turned profitable in 2019.
- Byju's investor list includes Sequoia Capital India, Chan Zuckerberg Initiative (CZI), Tencent, Sofina, Lightspeed Venture Partners and now Silver Lake Partners amongst others.

## Aakash Educational Services Limited:

- Aakash provides comprehensive test preparatory services for students preparing for Entrance Examinations, School/Board Exams and Competitive Exams.

- Company has a pan India network of 215+ Aakash Centers and a student count of more than 250,000. PE fund Blackstone is an investor of around 37.5% stake in AESL (valuing Aakash at around \$500 Million in 2019; with this deal Blackstone almost doubled its investment in AESL within less than 2 years.)

### Rationale:

- Byju's is disrupting the Indian education space with technology and with this acquisition it is adding offline teaching capabilities to its platform. It said that partnership combines Aakash's pedagogy expertise in the test-prep segment with BYJU'S content and tech capabilities. Complementary strengths of Byju's and Aakash will enable Byju's to build capabilities, create engaging and personalized learning programs. Aakash will expand by adding 100 to 150 more physical centers with support from Byju's and centers of Aakash will be physical point of contact for services of Byju's as well creating synergies for both groups.
- Byju is on a fundraising spree in last few years with valuations at approx. \$14 to 15 billion in latest series F fund raising of \$460 million from MC global and B capital amongst other investors. Byju has also acquired US based OSMO in 2019 and startup Whitehat Jr. which teaches coding for \$300 Mn in August 20.
- Last, an interesting fact: Aakash Chaudhri (MD AESL), Amit Jain (ex-senior MD Blackstone) and Amit Khanna (deal advisor to Aakash) who have shaped this deal are all Indian School of Business (ISB Hyderabad) alumni.

## Transaction:

- Piramal Pharma Limited to acquire a 100% stake in Hemmo Pharmaceuticals Pvt. Ltd. for an upfront consideration of Rs.775 crores and earn-outs linked to achievement of milestones. Consequent to this acquisition, Hemmo will become a wholly owned subsidiary of Piramal Pharma.

## Piramal Pharma Limited:

- Piramal Pharma Limited is a subsidiary of Piramal Enterprises Limited and is headquartered in Mumbai. It offers a portfolio of products and services through manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries.
- In October PPL has received 20% growth investment from Carlyle Group.

## Hemmo Pharmaceuticals Pvt. Ltd.:

- Hemmo Pharmaceuticals Pvt. Ltd. is a manufacturer of Peptide-based pharmaceuticals. Its portfolio covers 30+ APIs including generic peptides, peptide NCEs and peptides in clinical development which it offers to pharma and research companies in both domestic and global markets.
- Its manufacturing facility located at Turbhe is certified by the USFDA, EDQM and WHO and its R&D facility located at Thane. Hemmo's turnover in FY 19-20 was Rs. 85 Crore.

## Rationale:

- This acquisition marks Piramal Pharma's foray into the development and manufacturing of peptide APIs, a capability that complements its existing service offering. Peptide is a compound of two or more amino acids and manufacturing it is complex. Peptide APIs have seen increased use in oncology, treatment of diabetes and obesity. The growth in therapies for rare diseases and orphan drugs has also increased the need for peptides.
- Hemmo is one of key manufacturers of synthetic peptides with a legacy of more than thirty-eight years in business supplying peptide products and custom peptide synthesis. Hemmo has expertise in both solution phase and solid phase synthesis of peptides.

# Private Equity Key Deals

### Transaction:

- Creador sold its stake in Ahmedabad based Corona Remedies to PE fund ChrysCapital. ChrysCapital paid Rs.6.7 billion (\$90 million) for a 30% stake, of which 20% came from Creador and 10% from the promoter group.
- The deal values Corona Remedies at around Rs. 2300 Crore as reported by Economic Times.

### Corona Remedies Pvt. Ltd.:

- Ahmedabad based Corona Remedies Pvt. Ltd.'s product range includes formulations in therapeutic segments like gynaecology, cardio diabetic, nutraceuticals, anti-infective and paediatrics.
- The company has also acquired various brands from GSK & Abbott. Company was found by Dr. Kirtibhai Mehta and his two sons Nirav & Ankur and is backed by team of over 3000 professionals including around 1900 medical representatives.

### Corona Remedies Pvt. Ltd.:

- Established in 1999, ChrysCapital is an India focused investment firm with approximately \$4 billion of assets under management across eight funds and series of successful exits.
- Its current portfolio consists of companies like Herofincorp, FirstCry, DreamSports, Intas pharma, Mankind, Eris pharma amongst others.



### Rationale:

- In 2016, Creador fund had invested INR1.18 billion in Corona Remedies for a minority stake and have said to made 35% IRR on their investment with this exit. Creador said that during their investment time frame the company's sale went up by 2.6 times and EBITDA went up by 8 times.
- Nirav Mehta, promoter of Corona commented that the Corona's market beating growth has been result of focusing on the gaps in the market and focus on affordability.
- Pharma API segment has become one of the most exciting segment in the deal space lately in Indian market which has traditionally favored the generics segment.
- Earlier the Chinese API players had dominated the markets due to strong price competition in the market. However in last few years many environmental curbs were placed on Chinese players due to their widely polluting nature. Global players are also de-risking their supply chains with china plus one strategy.
- Indian Government has also started Atmanirbhar initiative to reduce outside dependence. Indian API companies are increasingly doing very well presently and depending on the complexity and market of their products are commanding very attractive valuations.

## Acknowledgements:

RBI Bulletin ([www.bulletin.rbi.org.in](http://www.bulletin.rbi.org.in)), SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)), BSE ([www.bseindia.com](http://www.bseindia.com))

## Disclaimer

This material has been prepared by the personnel in Vora Corporate Finance which is Investment Banking arm of Vora Management Consultancy Private Limited and looks after fund raising, valuations and M&A. Any views or opinions expressed herein are solely that of individual authors and may differ from view of Vora Management Consultancy Private Limited. This material is proprietary to Vora Management Consultancy Private Limited and is for your personal use only. Any distribution, copy, reprints or forward to others is strictly prohibited.

This material captures the information based on information available in the public domain, public announcements and sources believed to be reliable. Analysis contained herein is based on publicly available information and appropriate assumptions. This material is intended merely to highlight market developments and is not intended to be comprehensive and does not constitute strategic, investment, legal or tax advice. In no event Vora Management Consultancy Private Limited be liable for any use by any party or for any decision made or action taken by any party in reliance upon, or for any inaccuracies or errors in, or omissions from, the information contained herein and such information may not be relied upon by you for evaluating any transaction.